Generalized Essential Telangiectasia
- Author: David Green, MD, PA; Chief Editor: Dirk M Elston, MD more...
A telangiectasis refers to a visibly dilated blood vessel on the skin or mucosal surface. Telangiectases that develop in the absence of any preceding or coexisting cutaneous or systemic disease are considered to be primary or essential. Telangiectases resulting from or in association with a known disease state are classified as secondary.
Different presentations of primary telangiectases have been arbitrarily classified as distinct syndromes, designated by terms that often are descriptive based on inheritance, age of onset, anatomic distribution, morphology, prognosis, or associated findings. No recognized nomenclature exists for these telangiectatic disorders. Generalized essential telangiectasia refers to one syndrome of acquired primary telangiectases that are so termed because of their widespread anatomic distribution.
The pathophysiologic factors causing blood vessel dilatation in generalized essential telangiectasia are yet to be elaborated. Familial cases have been reported with an autosomal dominant pattern of inheritance.
Neither the incidence nor prevalence of generalized essential telangiectasia is known.
Generalized essential telangiectasia has been reported more commonly in whites, perhaps because of the marked contrast of the vessels on light-complexioned skin.
Women are affected more commonly than are men, and in one published study of 13 people with generalized essential telangiectasia, 10 of the reported patients were women.
In one report of 13 patients, the average age of onset for generalized essential telangiectasia was 38 years.
Rothe MJ, Grant-Kels JM. Nomenclature of the primary telangiectasias. Int J Dermatol. 1992 May. 31(5):320. [Medline].
McGrae JD, Winkelmann RK. Generalized essential telangiectasia: Report of a clinical and histochemical study of 13 patients with acquired cutaneous lesions. JAMA. 1963 Sep 21. 185:909-13. [Medline].
Ali MM, Teimory M, Sarhan M. Generalized essential telangiectasia with conjunctival involvement. Clin Exp Dermatol. 2006 Nov. 31(6):781-2. [Medline].
Gantenbein C, Seiter S, Weik R, Reinhold U, Ruprecht KW, Tilgen W. [Ocular manifestation of progressive essential telangiectases]. J Fr Ophtalmol. 2001 Jan. 24(1):45-8. [Medline].
Mannis MJ, Bindi CS, Huntley AC. Ocular manifestations of generalized essential telangiectasia. Cornea. 1999 Nov. 18(6):731-3. [Medline].
Seiter S, Gantenbein C, Ugurel S, Ruprecht KW, Tilgen W, Reinhold U. An oculocutaneous presentation of essential progressive telangiectasia. Br J Dermatol. 1999 May. 140(5):969-71. [Medline].
Swensson B, Swensson O, Häring G. [Progressive disseminated essential telangiectasia with conjunctival involvement]. Klin Monatsbl Augenheilkd. 1998 Feb. 212(2):116-9. [Medline].
Person JR, Longcope C. Estrogen and progesterone receptors are not increased in generalized essential telangiectasia. Arch Dermatol. 1985 Jul. 121(7):836-7. [Medline].
Sadick NS, Niedt GW. A study of estrogen and progesterone receptors in spider telangiectasias of the lower extremities. J Dermatol Surg Oncol. 1990 Jul. 16(7):620-3. [Medline].
Thieu KP, Haynes HA. Generalized essential telangiectasia with predilection for surgical scar. J Am Acad Dermatol. 2009 Apr. 60(4):710-1. [Medline].
Wells RS, Dowling GB. Hereditary benign telangiectasia. Br J Dermatol. 1971 Jan. 84(1):93-4. [Medline].
Checketts SR, Burton PS, Bjorkman DJ, Kadunce DP. Generalized essential telangiectasia in the presence of gastrointestinal bleeding. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 2):321-5. [Medline].
Braverman IM. Ultrastructure and organization of the cutaneous microvasculature in normal and pathologic states. J Invest Dermatol. 1989 Aug. 93(2 Suppl):2S-9S. [Medline].
Wenzel SM, Hohenleutner U, Landthaler M. Progressive disseminated essential telangiectasia and erythrosis interfollicularis colli as examples for successful treatment with a high-intensity flashlamp. Dermatology. 2008. 217(3):286-90. [Medline].
Green D. Sclerotherapy treatment insights. Dermatol Clin. 1998 Jan. 16(1):195-211. [Medline].
Shelley WB. Essential progressive telangiectasia. Successful treatment with tetracycline. JAMA. 1971 May 24. 216(8):1343-4. [Medline].
Shelley WB, Shelley ED. Essential progressive telangiectasia in an autoimmune setting: successful treatment with acyclovir. J Am Acad Dermatol. 1989 Nov. 21(5 Pt 2):1094-6. [Medline].
Shelley WB, Fierer JA. Focal intravascular coagulation in progressive ascending telangiectasia: ultrastructural studies of ketoconazole-induced involution of vessels. J Am Acad Dermatol. 1984 May. 10(5 Pt 2):876-87. [Medline].
Buscaglia DA, Conte ET. Successful treatment of generalized essential telangiectasia with the 585-nm flashlamp-pumped pulsed dye laser. Cutis. 2001 Feb. 67(2):107-8. [Medline].
Gambichler T, Avermaete A, Wilmert M, Altmeyer P, Hoffmann K. Generalized essential telangiectasia successfully treated with high-energy, long-pulse, frequency-doubled Nd:YAG laser. Dermatol Surg. 2001 Apr. 27(4):355-7. [Medline].
Blume JE. Generalized essential telangiectasia: a case report and review of the literature. Cutis. 2005 Apr. 75(4):223-4. [Medline].